Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
- Conditions
- Cataract
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- NTC srl
- Target Recruit Count
- 125
- Registration Number
- NCT03740659
- Locations
- 🇮🇹
ASST Santi Paolo e Carlo di Milano - P.O. San Paolo di Milano, Milano, MI, Italy
🇮🇹A.O.U. Pisana - P.O. di Cisanello, Pisa, PI, Italy
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
- Conditions
- Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 82
- Registration Number
- NCT03731832
- Locations
- 🇩🇪
Kliniken Ostalb Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany
🇩🇪phase drei Hämato-Onkologischer Studienkreis am Klinikum Aschaffenburg, Aschaffenburg, Germany
🇩🇪Sozialstiftung Bamberg / Klinik am Bruderwald, Zentrum für Innere Medizin, Med. Klinik V, Hämatologie und internistische Onkologie, Bamberg, Germany
Ultrasound Guided Intermediate Cervical Plexus Block in Thyroid Surgery
- Conditions
- Postoperative Pain
- Interventions
- Drug: local anestheticDrug: Dexamethasone
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT03731468
- Locations
- 🇪🇬
Assiut university, Assiut, Egypt
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 250
- Registration Number
- NCT03729804
- Locations
- 🇺🇸
University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
- Conditions
- NK-Cell LeukemiaPeripheral T Cell LymphomaNK-Cell Lymphoma
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 40
- Registration Number
- NCT03719105
- Locations
- 🇺🇸
Children's Hospital Orange County, Orange, California, United States
🇺🇸Helen De Vos, Grand Rapids, Michigan, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
- Conditions
- Refractory Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 41
- Registration Number
- NCT03713294
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Dysphagia Following Anterior Cervical Spine Surgery; Single Dose Steroid vs Saline (DysDexVSSal)
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- West Virginia University
- Target Recruit Count
- 80
- Registration Number
- NCT03711474
- Locations
- 🇺🇸
West Virginia University Department of Orthopaedics, Morgantown, West Virginia, United States
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT03710772
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 709
- Registration Number
- NCT03710603
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Australia
🇩🇰Odense University Hospital, Odense, Denmark
🇫🇷CHRU Hôtel Dieu, Nantes, France
International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia
- Conditions
- Acute Lymphoblastic Leukemia RecurrentAcute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, AdultAcute Lymphoblastic Leukemia, Pediatric
- Interventions
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 12
- Registration Number
- NCT03705507
- Locations
- 🇬🇧
King's College Hospital, London, United Kingdom
🇳🇱Prinses Maxima Centrum Voor Kinderoncologie, Utrecht, Netherlands
🇬🇧Birmingham Children's Hospital, Birmingham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.